Goldman Sachs Call 300 AMGN 16.08.../ DE000GG4RVQ3 /
8/2/2024 10:33:39 AM | Chg.+0.18 | Bid7:32:57 PM | Ask7:32:57 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
3.38EUR | +5.63% | 3.03 Bid Size: 10,000 |
3.06 Ask Size: 10,000 |
Amgen Inc | 300.00 USD | 8/16/2024 | Call |
GlobeNewswire
6/27
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 M...
GlobeNewswire
6/27
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All ...
GlobeNewswire
6/20
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7...
GlobeNewswire
6/19
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
GlobeNewswire
6/18
CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Confere...
GlobeNewswire
6/17
FDA Approves Phase II Clinical Trial for Ruxoprubart in ANCA Associated Vasculitis (AAV) – a Chronic...
GlobeNewswire
6/17
Solid Power Appoints Renewables Industry Veteran Linda Heller as Chief Financial Officer
GlobeNewswire
5/30
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affa...
GlobeNewswire
5/28
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
GlobeNewswire
5/27
Samsung Bioepis Announces Oral Presentation on Switching Period Results for SB16, a Proposed Biosimi...
GlobeNewswire
5/23
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...
GlobeNewswire
5/22
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...